Modified vaccinia ankara
- Generic Name
- Modified vaccinia ankara
- Brand Names
- Jynneos
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- TU8J357395
- Background
Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).
- Indication
Modified vaccinia ankara is a vaccine indicated for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. In the EU, it is additionally indicated for the prevention of other diseases caused by the vaccinia virus.
- Associated Conditions
- Ebola Virus Disease, Monkeypox, Variola Major (Smallpox)
- Associated Therapies
- -
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2025-01-06
- Target Recruit Count
- 450
- Registration Number
- NCT05740982
- Locations
- ๐บ๐ธ
Emory University School of Medicine, Atlanta, Georgia, United States
๐บ๐ธKaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
๐บ๐ธDuke Vaccine and Trials Unit, Durham, North Carolina, United States
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-10-08
- Target Recruit Count
- 229
- Registration Number
- NCT05512949
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธUniversity of California, San Diego (UCSD) - Antiviral Research Center (AVRC), San Diego, California, United States
๐บ๐ธVanderbilt University Medical Center, Nashville, Tennessee, United States
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
- Conditions
- Colorectal CarcinomaLynch Syndrome
- Interventions
- Biological: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPProcedure: Biospecimen CollectionBiological: MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSPProcedure: Endoscopic BiopsyOther: Questionnaire Administration
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT05078866
- Locations
- ๐บ๐ธ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธM D Anderson Cancer Center, Houston, Texas, United States
Modified Vaccinia Ankara (MVA) Vaccine Study
- Conditions
- Nasopharyngeal NeoplasmsEpstein-Barr Virus Infections
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 18
- Registration Number
- NCT01256853
- Locations
- ๐ญ๐ฐ
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.